Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 November 2006, Vol. 108, No. 10, pp. 3295-3301.
Prepublished online as a Blood First Edition Paper on July 27, 2006; DOI 10.1182/blood-2006-05-021113.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-05-021113v1
108/10/3295    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Oers, M. H. J.
Right arrow Articles by Hagenbeek, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Oers, M. H. J.
Right arrow Articles by Hagenbeek, A.
Related Collections
Right arrow Clinical Trials and Observations
Right arrow Neoplasia
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Marinus H. J. van Oers, Richard Klasa, Robert E. Marcus, Max Wolf, Eva Kimby, Randy D. Gascoyne, Andrew Jack, Mars van't Veer, Andrej Vranovsky, Harald Holte, Martine van Glabbeke, Ivana Teodorovic, Cynthia Rozewicz, and Anton Hagenbeek

From the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group, Hemato-Oncologie voor Volwassenen Nederland (HOVON), National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) (Canada), British National Lymphoma Investigation (BNLI), Australasian Leukaemia and Lymphoma Group (ALLG), Nordic Lymphoma Group (NLG), and EORTC Data Center.

We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). A total of 465 patients were randomized to induction with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (every 3 weeks) or R-CHOP (R: 375 mg/m2 intravenously, day 1). Those in complete remission (CR) or partial remission (PR) were randomized to maintenance with R (375 mg/m2 intravenously once every 3 months for a maximum of 2 years) or observation. R-CHOP induction yielded an increased overall response rate (CHOP, 72.3%; R-CHOP, 85.1%; P < .001) and CR rate (CHOP, 15.6%; R-CHOP, 29.5%; P < .001). Median progression-free survival (PFS) from first randomization was 20.2 months after CHOP versus 33.1 months after R-CHOP (hazard ratio [HR], 0.65; P < .001). Rituximab maintenance yielded a median PFS from second randomization of 51.5 months versus 14.9 months with observation (HR, 0.40; P < .001). Improved PFS was found both after induction with CHOP (HR, 0.30; P < .001) and R-CHOP (HR, 0.54; P = .004). R maintenance also improved overall survival from second randomization: 85% at 3 years versus 77% with observation (HR, 0.52; P = .011). This is the first trial showing that in relapsed/resistant FL rituximab maintenance considerably improves PFS not only after CHOP but also after R-CHOP induction.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Follicular lymphoma: chemotherapy and/or antibodies?
Michele Ghielmini
Blood 2006 108: 3235. [Full Text] [PDF]



This article has been cited by other articles:


Home page
JCOHome page
C. Sebban, P. Brice, R. Delarue, C. Haioun, B. Souleau, N. Mounier, N. Brousse, P. Feugier, H. Tilly, P. Solal-Celigny, et al.
Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study
J. Clin. Oncol., July 20, 2008; 26(21): 3614 - 3620.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
L. Arcaini, F. Montanari, E. P. Alessandrino, A. Tucci, E. Brusamolino, L. Gargantini, R. Cairoli, P. Bernasconi, F. Passamonti, M. Bonfichi, et al.
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Ann. Onc., July 1, 2008; 19(7): 1331 - 1335.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Hagenbeek, O. Gadeberg, P. Johnson, L. Moller Pedersen, J. Walewski, A. Hellmann, B. K. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, et al.
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Blood, June 15, 2008; 111(12): 5486 - 5495.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
I. F. Khouri, P. McLaughlin, R. M. Saliba, C. Hosing, M. Korbling, M. S. Lee, L. J. Medeiros, L. Fayad, F. Samaniego, A. Alousi, et al.
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Blood, June 15, 2008; 111(12): 5530 - 5536.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. J. Bishton, M. F. Leahy, R. J. Hicks, J. H. Turner, A. D. McQuillan, and J. F. Seymour
Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab
Ann. Onc., June 2, 2008; (2008) mdn172v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Cartron, L. Zhao-Yang, M. Baudard, T. Kanouni, V. Rouille, P. Quittet, B. Klein, and J.-F. Rossi
Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study
J. Clin. Oncol., June 1, 2008; 26(16): 2725 - 2731.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist, June 1, 2008; 13(6): 657 - 667.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
D. Malesci and G. La Montagna
Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab
Rheumatology, May 1, 2008; 47(5): 734 - 735.
[Full Text] [PDF]


Home page
BloodHome page
M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
Blood, May 1, 2008; 111(9): 4664 - 4667.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. Pettengell, C. Donatti, P. Hoskin, C. Poynton, P. J. Kettle, B. Hancock, S. Johnson, M. J. S. Dyer, S. Rule, M. Walker, et al.
The impact of follicular lymphoma on health-related quality of life
Ann. Onc., March 1, 2008; 19(3): 570 - 576.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
J. M. Vose
Maintenance Rituximab-Should It Be Given to Every Patient with Follicular Lymphoma?
ASCO Educational Book, January 1, 2008; 2008(1): 386 - 390.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
N. A. Bakker and G. W. van Imhoff
Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention?
Haematologica, November 1, 2007; 92(11): 1447 - 1450.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Taskinen, M.-L. Karjalainen-Lindsberg, H. Nyman, L.-M. Eerola, and S. Leppa
A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone
Clin. Cancer Res., October 1, 2007; 13(19): 5784 - 5789.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al.
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Blood, October 1, 2007; 110(7): 2569 - 2577.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res., September 15, 2007; 13(18): 5636s - 5642s.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
O. Weingart, F. A. Rehan, H. Schulz, F. Naumann, I. Knauel, C. B. J. Bohlius, and A. Engert
Sixth Biannual Report of the Cochrane Haematological Malignancies Group Focus on Non-Hodgkin Lymphoma
J Natl Cancer Inst, September 5, 2007; 99(17): E1 - E1.
[Full Text] [PDF]


Home page
Integr Cancer TherHome page
B. M. Berkson, D. M. Rubin, and A. J. Berkson
Reversal of Signs and Symptoms of a B-Cell Lymphoma in a Patient Using Only Low-Dose Naltrexone
Integr Cancer Ther, September 1, 2007; 6(3): 293 - 296.
[PDF]


Home page
JCOHome page
A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman
Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up
J. Clin. Oncol., June 20, 2007; 25(18): 2554 - 2559.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. H.J. van Oers
Rituximab maintenance therapy: a step forward in follicular lymphoma
Haematologica, June 1, 2007; 92(6): 826 - 833.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. G. Gribben
How I treat indolent lymphoma
Blood, June 1, 2007; 109(11): 4617 - 4626.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
H. Schulz, J. F. Bohlius, S. Trelle, N. Skoetz, M. Reiser, T. Kober, G. Schwarzer, M. Herold, M. Dreyling, M. Hallek, et al.
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
J Natl Cancer Inst, May 2, 2007; 99(9): 706 - 714.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
S. Vigouroux, M. Michallet, R. Porcher, M. Attal, L. Ades, M. Bernard, D. Blaise, R. Tabrizi, F. Garban, J.-P. Cassuto, et al.
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
Haematologica, May 1, 2007; 92(5): 627 - 634.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology, January 1, 2007; 2007(1): 216 - 225.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
C. Bello and E. M. Sotomayor
Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond
Hematology, January 1, 2007; 2007(1): 233 - 242.
[Abstract] [Full Text] [PDF]


Home page
JWatch Oncology and HematologyHome page
Rituximab for Resistant Follicular Non-Hodgkin Lymphoma
Journal Watch Oncology and Hematology, December 18, 2006; 2006(1218): 5 - 5.
[Full Text]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020